122 related articles for article (PubMed ID: 9449632)
1. Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone.
Chen TJ; Kuo CB; Tsai KF; Liu JW; Chen DY; Walker AM
Endocrinology; 1998 Feb; 139(2):609-16. PubMed ID: 9449632
[TBL] [Abstract][Full Text] [Related]
2. Dissociation of Janus kinase 2 and signal transducer and activator of transcription 5 activation after treatment of Nb2 cells with a molecular mimic of phosphorylated prolactin.
Coss D; Kuo CB; Yang L; Ingleton P; Luben R; Walker AM
Endocrinology; 1999 Nov; 140(11):5087-94. PubMed ID: 10537136
[TBL] [Abstract][Full Text] [Related]
3. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice.
Xu X; Kreye E; Kuo CB; Walker AM
Cancer Res; 2001 Aug; 61(16):6098-104. PubMed ID: 11507059
[TBL] [Abstract][Full Text] [Related]
4. Biological activity and immunological reactivity of human prolactin mutants.
Rhee HK; Sun Z; Kim SS; Goffin V; Martial JA; Dannies PS
Endocrinology; 1995 Nov; 136(11):4990-5. PubMed ID: 7588233
[TBL] [Abstract][Full Text] [Related]
5. Amino acids in highly conserved regions near the C-terminus of rat prolactin (PRL) play critical roles similar to those in binding of human GH to the PRL receptor.
Kato Y; Maruyama O; Chung HO; Tomizawa K; Kato T
Biochem Biophys Res Commun; 1996 May; 222(2):547-52. PubMed ID: 8670242
[TBL] [Abstract][Full Text] [Related]
6. Alanine-scanning mutagenesis of human prolactin: importance of the 58-74 region for bioactivity.
Goffin V; Norman M; Martial JA
Mol Endocrinol; 1992 Sep; 6(9):1381-92. PubMed ID: 1435787
[TBL] [Abstract][Full Text] [Related]
7. Dephosphorylation of standard prolactin produces a more biologically active molecule: evidence for antagonism between nonphosphorylated and phosphorylated prolactin in the stimulation of Nb2 cell proliferation.
Wang YF; Walker AM
Endocrinology; 1993 Nov; 133(5):2156-60. PubMed ID: 8404666
[TBL] [Abstract][Full Text] [Related]
8. Both prolactin (PRL) and a molecular mimic of phosphorylated PRL, S179D-PRL, protect the hippocampus of female rats against excitotoxicity.
Morales T; Lorenson M; Walker AM; Ramos E
Neuroscience; 2014 Jan; 258():211-7. PubMed ID: 24252319
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL.
Schroeder MD; Brockman JL; Walker AM; Schuler LA
Endocrinology; 2003 Dec; 144(12):5300-7. PubMed ID: 12970160
[TBL] [Abstract][Full Text] [Related]
10. A major prolactin-binding complex on human milk fat globule membranes contains cyclophilins A and B: the complex is not the prolactin receptor.
Lorenson MY; Ueda EK; Chen KE; Walker AM
Am J Physiol Endocrinol Metab; 2012 Mar; 302(5):E585-94. PubMed ID: 22205628
[TBL] [Abstract][Full Text] [Related]
11. A molecular mimic of phosphorylated prolactin (S179D PRL) secreted by eukaryotic cells has a conformation with an increased positive surface charge compared to that of unmodified prolactin.
Ueda EK; Soares CR; Bartolini P; DeGuzman A; Lorenson MY; Walker AM
Biochemistry; 2009 Jul; 48(29):6887-97. PubMed ID: 19555049
[TBL] [Abstract][Full Text] [Related]
12. Central infusions of the recombinant human prolactin receptor antagonist, S179D-PRL, delay the onset of maternal behavior in steroid-primed, nulliparous female rats.
Bridges R; Rigero B; Byrnes E; Yang L; Walker A
Endocrinology; 2001 Feb; 142(2):730-9. PubMed ID: 11159845
[TBL] [Abstract][Full Text] [Related]
13. Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay.
Goffin V; Kinet S; Ferrag F; Binart N; Martial JA; Kelly PA
J Biol Chem; 1996 Jul; 271(28):16573-9. PubMed ID: 8663214
[TBL] [Abstract][Full Text] [Related]
14. Characterization of lactogen receptor-binding site 1 of human prolactin.
Kinet S; Goffin V; Mainfroid V; Martial JA
J Biol Chem; 1996 Jun; 271(24):14353-60. PubMed ID: 8662911
[TBL] [Abstract][Full Text] [Related]
15. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
Llovera M; Pichard C; Bernichtein S; Jeay S; Touraine P; Kelly PA; Goffin V
Oncogene; 2000 Sep; 19(41):4695-705. PubMed ID: 11032019
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism of prolactin secreted by human prolactinoma cells: immunological, receptor binding, and biological properties of the glycosylated and nonglycosylated forms.
Pellegrini I; Gunz G; Ronin C; Fenouillet E; Peyrat JP; Delori P; Jaquet P
Endocrinology; 1988 Jun; 122(6):2667-74. PubMed ID: 3131120
[TBL] [Abstract][Full Text] [Related]
17. Unmodified prolactin (PRL) and S179D PRL-initiated bioluminescence resonance energy transfer between homo- and hetero-pairs of long and short human PRL receptors in living human cells.
Tan D; Johnson DA; Wu W; Zeng L; Chen YH; Chen WY; Vonderhaar BK; Walker AM
Mol Endocrinol; 2005 May; 19(5):1291-303. PubMed ID: 15695371
[TBL] [Abstract][Full Text] [Related]
18. Development of a constitutively active mutant form of the prolactin receptor, a member of the cytokine receptor family.
Gourdou I; Gabou L; Paly J; Kermabon AY; Belair L; Djiane J
Mol Endocrinol; 1996 Jan; 10(1):45-56. PubMed ID: 8838144
[TBL] [Abstract][Full Text] [Related]
19. Administration of unmodified prolactin (U-PRL) and a molecular mimic of phosphorylated prolactin (PP-PRL) during rat pregnancy provides evidence that the U-PRL:PP-PRL ratio is crucial to the normal development of pup tissues.
Yang L; Kuo CB; Liu Y; Coss D; Xu X; Chen C; Oster-Granite ML; Walker AM
J Endocrinol; 2001 Feb; 168(2):227-38. PubMed ID: 11182760
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the receptor binding and Nb2 proliferation activities of rat prolactin by site-directed mutagenesis.
Kato Y; Tomizawa K; Kato T
Zoolog Sci; 1997 Feb; 14(1):147-52. PubMed ID: 9200987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
